Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 183

Sort by

Sort Order Select

Journal Articles

Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry

Blood (2019) 134 (Supplement_1): 1321.

https://doi.org/10.1182/blood-2019-128568

Published: 2019

Journal Articles

Targeting Sirt6 with OSS_128167 Displays Anti-Tumor Activities in Diffuse Large B-Cell Lymphoma through Down-Regulation of PI3K Signaling

Juan Yang, MM, Xiangxiang Zhou, MD, Ying Li, MD, Ya Zhang, MD, Xiaosheng Fang, MD, Na Chen, MD, Xin Wang, MD PhD

Blood (2019) 134 (Supplement_1): 5065.

https://doi.org/10.1182/blood-2019-127926

Published: 2019

Journal Articles

Vaccination with Live Attenuated Virus Vaccines in Four Pediatric Patients with CML While on Imatinib Treatment

Claudia Bettoni Da Cunha-Riehm, MD, Verena Hildebrand, MD, Michaela Nathrath, MD PhD, Markus Metzler, MD PhD, Meinolf Suttorp, MD PhD

Blood (2019) 134 (Supplement_1): 5903.

https://doi.org/10.1182/blood-2019-122219

Published: 2019

Journal Articles

Lymphatic Control of the Tumor Immune Microenvironment

Melody A. Swartz, PhD

Blood (2019) 134 (Supplement_1): SCI-46.

https://doi.org/10.1182/blood-2019-123389

Published: 2019

Journal Articles

New Insights into Heme Utilization Pathways

Emanuela Tolosano, PhD

Blood (2019) 134 (Supplement_1): SCI-25.

https://doi.org/10.1182/blood-2019-121068

Published: 2019

Journal Articles

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

Anthony Quagliano, BS, Anilkumar Gopalakrishnapillai, PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 2628.

https://doi.org/10.1182/blood-2019-129198

Published: 2019

Journal Articles

Benefits of Ehl Factor VIII Replacement Therapy in Hemophilia: Observations on Coverage, Physical Activity and Phisiotherapy

Felipe Querol, MD PhD, Sofía Pérez-Alenda, PhD, Juan Eduardo Megias, Juan José Carrasco, MSc, Marta Aguilar, PhD, Saturnino Haya, MD, Ana R Cid, Santiago Bonanad Boix, MD

Blood (2019) 134 (Supplement_1): 2455.

https://doi.org/10.1182/blood-2019-125651

Published: 2019

Journal Articles

Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells

Jacqueline Cloos, PhD, Godefridus J Peters, PhD, Marjon Al, BSc, Yehuda G Assaraf, PhD, Lixia Wang, PhD, Jack W. Singer, MD, Jorge E. Cortes, MD, Gert J. Ossenkoppele, MD PhD, Gerrit Jansen, PhD

Blood (2018) 132 (Supplement 1): 3945.

https://doi.org/10.1182/blood-2018-99-114447

Published: 2018

Journal Articles

Blockade of the P2Y 12 signaling Pathway with Clopidogrel Restrains Treg Proliferation In Vivo during Sepsis and in Vitro

Harika Vemulapalli, BSc, Albayati Samara, MS, Alexander Y Tsygankov, PhD, Elisabetta Liverani, PhD

Blood (2018) 132 (Supplement 1): 2413.

https://doi.org/10.1182/blood-2018-99-114884

Published: 2018

Journal Articles

Adenosine Regulation of cAMP through Phosphodiesterases

Bunyan Teng, PhD, Daniel N Darlington, PhD, Andrew P Cap, MD PhD

Blood (2018) 132 (Supplement 1): 2424.

https://doi.org/10.1182/blood-2018-99-114929

Published: 2018

Journal Articles

Reversal of Chemoresistance in Leukemia Cells Using Synthetic Bisbenzylisoquinoline Derivatives

Martin Müller, Susanne Gerndt, Anja Arner, Yu-Kai Chao, Linus Schömig, Carina Atzberger, Martin Biel, Franz Bracher, Angelika Vollmar, Vera Binder, MD, Marco Keller, Christian Grimm, Karin Bartel

Blood (2018) 132 (Supplement 1): 3504.

https://doi.org/10.1182/blood-2018-99-111651

Published: 2018

Journal Articles

The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data

Blood (2018) 132 (Supplement 1): 1967.

https://doi.org/10.1182/blood-2018-99-112983

Published: 2018

Journal Articles

A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates Ucart Proliferation, Differentiation, and Tumor Killing

Matt L Cooper, PhD, Karl W. Staser, MD PhD, Julie Ritchey, Jessica Niswonger, Byung Ha Lee, PhD, Jaehan Park, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 2199.

https://doi.org/10.1182/blood-2018-99-117265

Published: 2018

Journal Articles

Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant

Enrique M. Ocio, MD, Paula Rodriguez Otero, MD, Sara Bringhen, MD, Stefania Oliva, Axel Nogai, MD, Michel Attal, MD PhD, Philippe Moreau, Dheepak Kanagavel, Thomas F Fitzmaurice, PhD, Junlong Wu, Joaquin Martinez Lopez, MD PhD

Blood (2018) 132 (Supplement 1): 595.

https://doi.org/10.1182/blood-2018-99-111244

Published: 2018

Journal Articles

Function of ASXL1 Mutations in Chronic Neutrophilic Leukemia

Theodore Braun, MD PhD, Amy Foley, MEng., Brian J. Druker, MD, Julia E. Maxson

Blood (2018) 132 (Supplement 1): 3067.

https://doi.org/10.1182/blood-2018-99-119213

Published: 2018

Journal Articles

Epigenetic Drug Combination Overcomes Bone Marrow Microenvironment-Induced Chemoprotection in Pediatric Acute Lymphoblastic Leukemia Via Modulation of CD81

Anthony Quagliano, BS, Anilkumar Gopalakrisnapillai, PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2018) 132 (Supplement 1): 3957.

https://doi.org/10.1182/blood-2018-99-120275

Published: 2018

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Alexey V Danilov, MD PhD, Charles Herbaux, MD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Simon Rule, MD, Ebenezer A Kio, MD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Lionel Karlin, MD, Christopher Fegan, MD

Blood (2018) 132 (Supplement 1): 3135.

https://doi.org/10.1182/blood-2018-99-113111

Published: 2018

Journal Articles

Dasatinib Effect on NK Cells and Anti-Tumor Immunity

Mieszko Lachota, Marta Siernicka, MSc, Zofia Pilch, PhD, Agnieszka Graczyk-Jarzynka, PhD, Magdalena Winiarska, PhD

Blood (2018) 132 (Supplement 1): 3004.

https://doi.org/10.1182/blood-2018-99-111280

Published: 2018

Journal Articles

Inhibition of PI3K Alpha and PI3K Delta with Copanlisib Shows Preclinical Activity As a Single Agent and in Combination in Multiple Myeloma

Sarah M Larson, MD, Mao Yu Peng, PhD, Monica Mead, MD BS, Andrae Vandross, MD, Dylan Conklin, PhD, Erika Von Euw, PhD, Dennis J. Slamon, MD PhD

Blood (2017) 130 (Supplement 1): 3084.

https://doi.org/10.1182/blood.V130.Suppl_1.3084.3084

Published: 2017

Journal Articles

The Proto-Oncogene Mer Is a Novel Therapeutic Target in Mantle Cell Lymphoma

Cunzhen Shi, Xiaogan Wang, MD, Ning Ding, MD, Lingyan Ping, Yuqin Song, MD, Jun Zhu, BS

Blood (2017) 130 (Supplement 1): 5138.

https://doi.org/10.1182/blood.V130.Suppl_1.5138.5138

Published: 2017

NARROW

Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry

Targeting Sirt6 with OSS_128167 Displays Anti-Tumor Activities in Diffuse Large B-Cell Lymphoma through Down-Regulation of PI3K Signaling

Vaccination with Live Attenuated Virus Vaccines in Four Pediatric Patients with CML While on Imatinib Treatment

Lymphatic Control of the Tumor Immune Microenvironment

New Insights into Heme Utilization Pathways

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

Benefits of Ehl Factor VIII Replacement Therapy in Hemophilia: Observations on Coverage, Physical Activity and Phisiotherapy

Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells

Blockade of the P2Y 12 signaling Pathway with Clopidogrel Restrains Treg Proliferation In Vivo during Sepsis and in Vitro

Adenosine Regulation of cAMP through Phosphodiesterases

Reversal of Chemoresistance in Leukemia Cells Using Synthetic Bisbenzylisoquinoline Derivatives

The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data

A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates Ucart Proliferation, Differentiation, and Tumor Killing

Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant

Function of ASXL1 Mutations in Chronic Neutrophilic Leukemia

Epigenetic Drug Combination Overcomes Bone Marrow Microenvironment-Induced Chemoprotection in Pediatric Acute Lymphoblastic Leukemia Via Modulation of CD81

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Dasatinib Effect on NK Cells and Anti-Tumor Immunity

Inhibition of PI3K Alpha and PI3K Delta with Copanlisib Shows Preclinical Activity As a Single Agent and in Combination in Multiple Myeloma

The Proto-Oncogene Mer Is a Novel Therapeutic Target in Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only